Evidences for oxidative stress in essential hypertension

• Autorzy: Tatjana Cvetković , Radmila Veličković-Radovanović , Vidojko Djordjević , Sonja Radenković , Predrag Vlahović , Nikola Stefanović
• Języki publikacji: EN

Abstrakty

EN

Słowa kluczowe

EN

Blood pressure; Hypertension; Oxidative stress

• Czasopismo: Open Medicine
• Rocznik: 2012
• Tom: 7
• Numer: 5
• Strony: 610-616

Daty

wydano

2012-10-01

online

2012-07-28

Twórcy

autor

Tatjana Cvetković,

autor

Radmila Veličković-Radovanović

• Departments of Nephrology, Clinical Center, 18000, Niš, Serbia

autor

Vidojko Djordjević

• Departments of Nephrology, Clinical Center, 18000, Niš, Serbia

autor

Sonja Radenković

• Departments of Nephrology, Clinical Center, 18000, Niš, Serbia

autor

Predrag Vlahović

• Departments of Biochemistry, Clinical Center, 18000, Niš, Serbia

autor

Nikola Stefanović

• Faculty of Medicine, University in Niš, 18000, Niš, Serbia

Bibliografia

• [1] Keaney JF, Larson MG, Vasan RS, Wilson WF, Lipinska I, Corey D, Massaro MJ, Sutherland P, Vita JA, Benjamin EJ (2003) Obesity and systemic oxidative stres. Clinical corelates of oxidative stress in the Framingham study. Hypertension 23(3): 432–449
• [2] Lacy F, Kailasam TM, O’Connor DT, Schmid-Schonbein GW, Parmer RJ (2000) Plasma hydrogen peroxide production in human essential hypertension. Role of heredity, gender and ethnicity. Hypertension 36(5): 878–884 http://dx.doi.org/10.1161/01.HYP.36.5.878[Crossref]
• [3] Swei A, Lacy F, DeLano FA, Schmid-Schonbein GW (1997) Oxidative stress in the DAHL hypertensive rat. Hypertension 30(6): 1628–1646 http://dx.doi.org/10.1161/01.HYP.30.6.1628[Crossref]
• [4] Lacy F, O’Connor DT, Schmid-Schonbein GW (1998) Plasma hydrogen peroxide production in hyper tensives and normotensive subjects at genetic risk of hypertension. J Hypertension 16: 291–303 http://dx.doi.org/10.1097/00004872-199816030-00006[Crossref]
• [5] Digiesi V, Lenuzza M, Digiesi G (2001) Prospects for use of antioxidant therapy in hypertension: Ann Ital Med Int 16:93–100 [PubMed]
• [6] Dobrian AD, Schriver SD, Prewitt RL (2001) Role of Angiotensin II and free radicals in blood pre ssure regulation in rat model of renal hypertension. Hypertension 38(3): 361–376 http://dx.doi.org/10.1161/01.HYP.38.3.361[Crossref]
• [7] Dobiasova M, Frohlich J (2001) The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esteri-fication rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 34(7): 583–588 http://dx.doi.org/10.1016/S0009-9120(01)00263-6[Crossref]
• [8] Andreeva IL, Kožemjakin AL, Kishkun AA (1988) Modifikacija metoda opredelenia perekisej lipidov v teste s tiobarbiturovoj kislotoj. Lab Delo 11: 41–43
• [9] Jain SK, Levine NS, Duett J, Hollier B (1990) Elevated lipid peroxidation levels in red blood cells of streptozotocin-treated diabetic rats. Metabolism 39(9): 971–975 http://dx.doi.org/10.1016/0026-0495(90)90310-9[Crossref]
• [10] Koraćević D, Koraćević G, ĐorĐević V, Andrejević S (1997) Simple method for the estimation of antioxidant activity in serum and other biological fluids. Balk J Clin Lab 3–4: 23–28
• [11] Koroljuk AM, Ivanova IL, Majorova GI, Tokarev IB (1988) Metod opredeljenja aktivnosti katalazi. Lab Delo 1: 16–18
• [12] Beutler E, Duron O, Kelly MB. (1963). Improved method for the determination of blood glutathione. J Lab Clin Med, 61, 882–888 [PubMed]
• [13] García-Donaire JA, Ruilope LM (2010) Recent advances in the management of hypertension. F1000 Med Rep 2: pii: 19
• [14] Ménard J, Chatellier G (1995) Limiting factors in the control of BP: why is there a gap between theory and practice? J Hum Hypertens 2: 19–23
• [15] Düsing R (2006) Overcoming barriers to effective blood pressure control in patients with hyper tension. Curr Med Res Opin 8: 1545–1553 http://dx.doi.org/10.1185/030079906X120995[Crossref]
• [16] Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ (1990) Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 86(1): 228–234 http://dx.doi.org/10.1172/JCI114688[Crossref]
• [17] Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23(2): 168–175. http://dx.doi.org/10.1161/01.ATV.0000051384.43104.FC[Crossref]
• [18] Papaharalambus CA, Griendling KK (2007) Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 17(2): 48–54 http://dx.doi.org/10.1016/j.tcm.2006.11.005[WoS][Crossref]
• [19] Schwartz GL, Turner ST (2004) Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 4(3): 151–160 http://dx.doi.org/10.2165/00129785-200404030-00002[Crossref]
• [20] Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY, Pepine CJ, Johnson JA (2008) INVEST Investigators: beta-adrenergic receptor gene polymorphisms and betablocker treatment outcomes in hypertension. Clin Pharmacol Ther 84(6): 715–721 http://dx.doi.org/10.1038/clpt.2008.139[WoS][Crossref]
• [21] Shin J, Johnson JA (2007) Pharmacogenetics of beta-blockers. Pharmacotherapy 27(6): 874–887 http://dx.doi.org/10.1592/phco.27.6.874[WoS][Crossref]
• [22] Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, Liu YZ, Li Q, Zhou HH (2006) beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 80(1): 23–32 http://dx.doi.org/10.1016/j.clpt.2006.03.004[Crossref]
• [23] Hadi HA, Carr CS, Al Suwaidi J (2005) Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 1(3): 183–198
• [24] Alexander WR (1995) Hypertension and the pathogenesis of atherosclerosis. Hypertension 25(2): 155–181 http://dx.doi.org/10.1161/01.HYP.25.2.155[Crossref]
• [25] Zou A-P, Li N, Cowley AW (2001) Production and actions of superoxide in the renal medulla. Hypertension 37(2): 547–565 http://dx.doi.org/10.1161/01.HYP.37.2.547[Crossref]
• [26] Wen Y, Killalea S, McGettigan P, Feely J (1996) Lipid peroxidation and antioxidant vitamin C and E in hypertensive patients. Ir J Med Sci 165(3): 210–212 http://dx.doi.org/10.1007/BF02940252[Crossref]
• [27] Tamer L, Sucu N, Polat G, Ercan B, Aytacoglu B, Yücebilgiç G, Unlü A, Dikmengil M, Atik U (2002) De creased serum total antioxidant status and erythrocyte-reduced glutathione levels are associated with increased serum malondialdehyde in atherosclerotic patients. Arch Med Res 33(3): 257–260 http://dx.doi.org/10.1016/S0188-4409(01)00381-2[Crossref]
• [28] D’souza A, Kurien BT, Rodgers R, Shenoi J, Kurono S, Matsumoto H, Hensley K, Nath SK, Scofield HR (2008) Detection of catalase as a major protein target of the lipid peroxidation product 4-HNE and the lack of its genetic association as a risk factor in SLE. BMC Medical Genetics 9: 62 http://dx.doi.org/10.1186/1471-2350-9-62[WoS][Crossref]
• [29] Zhou XF, Cui J, DeStefano AL, Chazaro I, Farrer LA, Manolis AJ, Gavras H, Baldwin CT (2005) Polymorphisms in the promoter region of catalase gene and essential hypertension. Dis Mar kers 21(1): 3–7 [Crossref]
• [30] Nandeesha N, Sathiyapriya V, Zachariah Bobby, Pavithran P, Agrawal A, Selvaraj N. (2007). Altered oxidant-antioxidant status in non-obese men with moderate essential hypertension. Indi an J Med Sci 61(6): 326–331 http://dx.doi.org/10.4103/0019-5359.32679[Crossref]
• [31] Yang H-Y, Kao P-F, Chen T-H, Tomlinson B, Ko W-C, Chan P (2007) Effects of the angiotensin ii type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients. J Clin Pharmacol 47: 397–403 http://dx.doi.org/10.1177/0091270006296762[Crossref]
• [32] Gomes A, Costa D, Lima JL, Fernandes E (2006) Antioxidant activity of beta-blockers: an effect medi ated by scavenging reactive oxygen and nitrogen species? Bioorg Med Chem 14(13): 4568–4577 http://dx.doi.org/10.1016/j.bmc.2006.02.023[Crossref]
• [33] Umemoto S, Tanaka M, Kawahara S, Kubo M, Umeji K, Hashimoto R, Matsuzaki M (2004) Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in strokeprone spontaneously hypertensive rats. Hypertens Res 27(11): 877–885 http://dx.doi.org/10.1291/hypres.27.877[Crossref]

Identyfikatory

DOI

10.2478/s11536-012-0043-7